Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo-controlled, double-blind trial.

Fiche publication

Date publication

octobre 2024

Journal

Annals of the rheumatic diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric

Tous les auteurs :
Ruyssen-Witrand A, Brusq C, Masson M, Bongard V, Salliot C, Poiroux L, Nguyen M, Roux CH, Richez C, Saraux A, Vergne-Salle P, Morel J, Flipo RM, Piperno M, Gottenberg JE, Marotte H, Soubrier M, Gossec L, Dieudé P, Lassoued S, Zabraniecki L, Couture G, Boyer JF, Jamard B, Degboe Y, Constantin A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39472058

Résumé

To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).